Maple Springs Of Palmer in Palmer, AK

Maple Springs Of Palmer is a medicare and medicaid certified nursing home in Palmer, Alaska. It is located in Matanuska-Susitna county at 12130 East Maple Springs Way, Palmer, Alaska 99645. You can reach out to the office of Maple Springs Of Palmer via phone at (907) 802-6641. This skilled nursing facility has 67 federally certified beds with average occupancy rate of 49.1%. Its legal business name is Maple Springs Of Palmer Snf Holdings, Llc and has the following ownership type - For Profit - Limited Liability Company.

Maple Springs Of Palmer (Medicare CCN 025039) is certified by CMS (Centers for Medicare & Medicaid Services) and participates in both medicare and medicaid program. This means if you are part of medicare or medicaid program, you may consider this nursing facility for your medical needs. It was first certified by CMS in 2020 (4 years certified) and the last quality survey was conducted in May, 2020.

Name	Maple Springs Of Palmer
Location	12130 East Maple Springs Way, Palmer, Alaska
Certified By	Medicare and Medicaid
No. of Certified Beds	67
Occupancy Rate	49.1%
Medicare ID (CCN)	025039
Legal Business Name	Maple Springs Of Palmer Snf Holdings, Llc
Ownership Type	For Profit - Limited Liability Company

Nursing Homes may have multiple NPI numbers. We have found possible NPI number/s associated with Maple Springs Of Palmer from NPPES records by matching pattern on the basis of name, address, phone number etc. Please use this information accordingly.
Nursing homes vary in the quality of care and services they provide to their residents. The below quality ratings for Maple Springs Of Palmer are calculated from three sources - health inspection results, staffing data, and quality measure data. This information gives you an indication of the care Maple Springs Of Palmer give to their patients.

Ratings from Surveys (Inspections):
Ratings from Quality Measures:
Ratings from Staffing Data:
Overall Rating:

News Archive

Ipilimumab in combination with paclitaxel/carboplatin for stage IIIb/IV NSCLC shows superior results

Ipilimumab used in combination with paclitaxel/carboplatin for stage IIIb/IV non-small cell lung cancer showed superior results in progression free survival when compared to paclitaxel/carboplatin alone, according to research presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (ISLAC) and the University of Chicago.

FDA approves Pfizer's Prevnar 13 to prevent pneumococcal disease in older children, adolescents

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted approval for the expansion of the company's pneumococcal conjugate vaccine, Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), for use in older children and adolescents aged 6 years through 17 years for active immunization for the prevention of invasive disease caused by the 13 Streptococcus pneumoniae serotypes contained in the vaccine.

Experts to meet in Cape Town to discuss development of vaccines for deadly airborne disease

At a time of growing global concern about the rising level of drug-resistant strains of tuberculosis in South Africa and worldwide, the world's top TB vaccine experts are meeting this week, the first time this scientific forum has been held in Africa, where they will present new research aimed at advancing development of vaccines against the deadly airborne disease.

St. Jude Medical gets European CE Mark approval for deep brain stimulation systems

St. Jude Medical, Inc., a global medical device company, today announced European CE Mark approval of its Brio, Libra and LibraXP deep brain stimulation systems for managing the symptoms of intractable primary and secondary dystonia, a neurological movement disorder that causes a person's muscles to contract and involuntarily spasm, reducing the ability to control movement.

Not all patients with CKD are destined for kidney failure

Not all patients with chronic kidney disease (CKD) are destined for kidney failure, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology.

Read more Medical News

› Verified 5 days ago

Number of Facility Reported Incidents	0
Number of Substantiated Complaints	0
Number of Fines	0
Total Amount of Fines in Dollars	$0
Number of Payment Denials	0
Total Number of Penalties	0

The resident survey data of Maple Springs Of Palmer is compared against the national average with the color code indicators: Better than National Average Worse than National Average

Experience Measure	Provider	National Avg.
Percentage of long-stay residents whose need for help with daily activities has increased	16.28	14.46
Percentage of long-stay residents who lose too much weight	6.67	5.51
Percentage of low risk long-stay residents who lose control of their bowels or bladder	10	48.41
Percentage of long-stay residents with a catheter inserted and left in their bladder	4.33	1.79
Percentage of long-stay residents with a urinary tract infection	2.04	2.65
Percentage of long-stay residents who have depressive symptoms	4.17	5.05
Percentage of long-stay residents who were physically restrained	0	0.23
Percentage of long-stay residents experiencing one or more falls with major injury	0	3.36
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine	94	93.87
Percentage of long-stay residents who received an antipsychotic medication	12	14.2
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine	88.03	83.88
Percentage of short-stay residents who newly received an antipsychotic medication	2.78	1.79
Percentage of long-stay residents whose ability to move independently worsened	38.01	17.09
Percentage of long-stay residents who received an antianxiety or hypnotic medication	34.78	19.7
Percentage of high risk long-stay residents with pressure ulcers	10.81	7.32